Skip to main content
. Author manuscript; available in PMC: 2024 Aug 28.
Published in final edited form as: J Infect Dis. 2015 Aug 27;213(2):191–198. doi: 10.1093/infdis/jiv403

Figure 1.

Figure 1.

Seroprevalence for any of the 9 types (6/11/16/18/31/33/45/52/58), any of the 7 HR types (16/18/31/33/45/52/58), HPV 16/18, and any of the 5 additional types (31/33/45/52/58) in the 9-valent vaccine, by age group, for females (A) and males (B). Abbreviations: HPV, human papillomavirus; HR, high-risk.